Doses above 2.4 mg weekly remain investigational without FDA approval for standard clinical use
Clinical trials suggest patients may lose 510% of body weight within the first 12 weeks, though individual outcomes differ
In this context, postbiotics are more plausibly positioned not as primary weight-loss interventions, but as nutritional strategies that may be continued after GLP-1based pharmacotherapy to support metabolic stability, mitigate weight regain, and preserve lean mass during the post-treatment phase ( From a clinical nutrition perspective, postbiotics should not be positioned as weight-loss agents, nor as substitutes for pharmacological GLP-1 receptor agonists
Also, it contains L-cysteine hydrochloride hydrate, a form of the only amino acid that contains sulfur
Layer two consists of formulation patents covering concentration, buffer systems, and preservatives, filed at Phase II (year 5 to 7, expires year 25 to 27)
Studies in animals show GLP1 activation can reduce seeking of things like sugary food, alcohol, nicotine, and even cocaine